Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05715372 · ClinicalTrials.gov registry record · NA

Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy

A NA study, sponsored by Rush University Medical Center.

Terminated
Registry status
NA
Development phase
5
Enrollment target

NCT05715372 is a NA study that was terminated before completion, run by Rush University Medical Center. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05715372, a NA study, was terminated before completion, sponsored by Rush University Medical Center.

TERMINATED
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

The GEMLIFE Study is a 12-month clinical trial for menopausal women. The purpose of this study is to promote an improved aging process for women in menopause through lifestyle changes. The changes will include a heart healthy diet, structured walking program, and mindfulness-based stress reduction. During the study, the investigators will monitor components of your genetic make-up that will tell us how you are aging. Investigators will also monitor bloodwork for inflammation that can affect medical conditions. Study participants may qualify if you are within 5 years of your last menstrual period and have well controlled medical conditions. There is no cost to participants to enroll in the study- only potential benefits to the participant's health and aging process.

Interventions

  • BEHAVIORAL Mediterranean diet
  • BEHAVIORAL Mindfulness-based stress reduction
  • BEHAVIORAL AHA walking program
  • BEHAVIORAL Unstructured Mediterranean diet
  • BEHAVIORAL Unstructured walking program

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2021-06-22
Est. Completion 2021-06-22
Phase NA

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT05715372

The ClinicalTrials.gov registry entry for NCT05715372 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which Mediterranean diet is the first listed.

NCT05715372 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05715372 about?

NCT05715372 is a clinical study titled "Genetic Evaluation and Modification of Lifestyles to Improve Female Life Expectancy". The GEMLIFE Study is a 12-month clinical trial for menopausal women. The purpose of this study is to promote an improved aging process for women in menopause through lifestyle changes. The changes will include a heart healthy diet, structured walking program, and mindfulness-based stress reduction. ...

What is the current status of trial NCT05715372?

This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2021-06-22. Estimated completion is 2021-06-22.

What interventions are being tested in trial NCT05715372?

The interventions under investigation include: Mediterranean diet (BEHAVIORAL), Mindfulness-based stress reduction (BEHAVIORAL), AHA walking program (BEHAVIORAL), Unstructured Mediterranean diet (BEHAVIORAL), Unstructured walking program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05715372?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.